Top Page
CanSino Biologics, Inc. Class H
(6185)
CanSino Biologics, Inc. Class H (6185) vs. iShares MSCI Hong Kong ETF (EWH)
CanSino Biologics, Inc. Class H Business Overview & Revenue Model
CanSino Biologics, Inc. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.00B | 846.34M | 345.18M | 1.03B | 4.30B | 24.89M |
| Gross Profit | 702.47M | 601.91M | -876.02M | -186.61M | 3.00B | 4.74M |
| EBITDA | -73.52M | -134.84M | -1.65B | -1.32B | 1.85B | -498.75M |
| Net Income | -139.45M | -378.88M | -1.48B | -909.43M | 1.91B | -396.64M |
Balance Sheet | ||||||
| Total Assets | 7.98B | 7.96B | 9.32B | 11.47B | 11.87B | 6.75B |
| Cash, Cash Equivalents and Short-Term Investments | 2.70B | 3.20B | 4.12B | 5.95B | 7.78B | 5.11B |
| Total Debt | 1.56B | 2.01B | 2.70B | 2.70B | 1.37B | 142.54M |
| Total Liabilities | 2.59B | 3.05B | 4.03B | 4.22B | 3.33B | 677.22M |
| Stockholders Equity | 5.39B | 4.91B | 5.27B | 6.75B | 8.00B | 6.07B |
Cash Flow | ||||||
| Free Cash Flow | -150.96M | -626.42M | -1.53B | -2.96B | 811.42M | -740.16M |
| Operating Cash Flow | 165.19M | -168.79M | -916.25M | -1.89B | 2.01B | -469.39M |
| Investing Cash Flow | 308.90M | 3.96M | -449.65M | -1.19B | -2.53B | -182.71M |
| Financing Cash Flow | -769.10M | -334.18M | -7.58M | 854.60M | 1.56B | 4.94B |
CanSino Biologics, Inc. Class H Technical Analysis
CanSino Biologics, Inc. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$44.07B | 9.43 | 7.86% | 7.13% | 1.13% | -13.53% | |
74 Outperform | HK$32.14B | 11.33 | 14.91% | 4.08% | -0.45% | 9.00% | |
73 Outperform | HK$233.12B | 44.35 | 16.09% | 0.95% | 8.68% | 0.82% | |
68 Neutral | HK$28.71B | 9.44 | 5.90% | 2.95% | ― | ― | |
65 Neutral | HK$75.44B | 16.05 | 6.75% | 1.66% | -1.12% | 76.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | HK$12.90B | -59.51 | -2.79% | ― | 29.21% | 80.37% |
CanSino Biologics, Inc. Class H Corporate Events
CanSino Biologics Inc. announced the successful passage of all resolutions at its 2025 second extraordinary general meeting, including amendments to the Articles of Association and the election of new independent non-executive directors. These changes, effective from November 27, 2025, are expected to enhance the company’s governance structure and strategic direction, potentially impacting its market positioning and stakeholder engagement.
CanSino Biologics Inc. has initiated a Phase I clinical trial in Indonesia for its inhaled tuberculosis booster vaccine, marking the completion of the first patient enrollment. This innovative vaccine aims to enhance the efficacy of the existing Bacillus Calmette-Guerin vaccine by stimulating a stronger immune response in the lungs, potentially controlling latent infections and preventing new ones. The trial will assess the safety and immunogenicity of the vaccine in adults, leveraging the company’s expertise in inhalation technology developed for COVID-19 vaccines.
CanSino Biologics Inc. has announced its 2025 second extraordinary general meeting, where significant amendments to corporate governance policies and the company’s Articles of Association will be discussed. The meeting will also address the appointment of new independent non-executive directors and the utilization of reserves to offset losses, indicating a strategic move to strengthen its governance framework and financial stability.
CanSino Biologics Inc. has announced a proposal to use its reserves to offset accumulated losses amounting to approximately RMB1.45 billion as of December 31, 2024. This strategic move, approved by the Board of Directors and pending shareholder approval, aims to enhance the company’s ability to deliver investor returns and support its high-quality development by reducing its accumulated losses to zero.
CanSino Biologics Inc. has established a Remuneration and Assessment Committee to enhance its corporate governance structure. This committee is responsible for evaluating the performance and remuneration of directors and senior management, which is expected to improve transparency and accountability within the company.
CanSino Biologics Inc. has announced significant changes to its corporate governance structure, including the proposed cancellation of its Board of Supervisors and amendments to its Articles of Association and corporate governance rules. These changes aim to enhance the company’s governance standards and streamline operations, with the audit committee taking over the functions of the Board of Supervisors. The proposed changes are subject to approval by shareholders at an extraordinary general meeting.
CanSino Biologics Inc. has established an Audit Committee to enhance its governance structure and ensure effective oversight and management by the board of directors. This move is aimed at improving the company’s internal control systems, facilitating communication with external audit firms, and assessing risks related to significant investments. The committee will consist of non-executive directors, with a majority being independent, to ensure unbiased supervision and verification of audits.
CanSino Biologics Inc. has established a Nomination Committee to enhance its corporate governance by standardizing the nomination procedures for directors and senior management. This move aims to improve the board’s composition and align with relevant regulations, potentially strengthening the company’s governance structure and market position.
CanSino Biologics Inc. has released its unaudited third-quarter financial report for the nine months ending September 30, 2025, showing a significant increase in operating revenue and net profit compared to the previous year. The company’s operating revenue rose by 22.13% to RMB 692.57 million, and net profit attributable to shareholders surged by 842.01% to RMB 14.44 million, indicating strong financial performance and potential positive implications for investors and stakeholders.
CanSino Biologics Inc. announced the successful passing of all resolutions at its 2025 first extraordinary general meeting, including the adoption of the 2025 H Share Option Scheme. The scheme involves granting a total of 860,000 H Share Options to key executives and senior management, which is expected to enhance the company’s operational capabilities and align the interests of its leadership with shareholders. This move is likely to strengthen CanSino Biologics’ position in the biotechnology sector, potentially impacting its market performance and stakeholder confidence.
CanSino Biologics Inc. has announced a board meeting scheduled for October 27, 2025, to review and approve the company’s third quarterly results for the period ending September 30, 2025. This meeting is crucial for stakeholders as it will provide insights into the company’s financial performance and strategic direction.
CanSino Biologics Inc. has announced the convening of its 2025 first extraordinary general meeting to discuss several key resolutions, including the adoption of the 2025 A Share Incentive Scheme and H Share Option Scheme. These initiatives are aimed at enhancing the company’s operational framework and incentivizing key personnel, which could potentially strengthen its market position and align stakeholders’ interests with the company’s growth objectives.
CanSino Biologics Inc. announced a supplemental update regarding its 2025 H Share Option Scheme, clarifying that the grant of H Share Options is contingent upon the scheme’s approval by shareholders at an upcoming Extraordinary General Meeting (EGM). The company plans to distribute a circular with more details about the scheme and the EGM notice to shareholders soon, which could impact the company’s stock option framework and shareholder engagement.
CanSino Biologics Inc. has announced the proposed adoption of the 2025 A Share Incentive Scheme and the 2025 H Share Option Scheme, aimed at incentivizing its directors, senior management, and other key personnel. These schemes are designed to enhance the company’s operational efficiency and align the interests of its stakeholders, pending approval at an Extraordinary General Meeting (EGM). The company plans to issue restricted shares and share options to eligible participants, which include 87 individuals, representing about 7.87% of its workforce.